FDA approves Moderna’s new lower-dose COVID-19 vaccine

The FDA has approved Moderna's new lower-dose COVID-19 vaccine, mNexspike, for adults 65 and older and individuals aged 12-64 with at least one health condition increasing their risk from the coronavirus; this approval mirrors the limitations placed on Novavax's COVID-19 vaccine. The new vaccine uses one-fifth of the dose of Moderna's existing Spikevax vaccine and has demonstrated comparable or superior efficacy in trials, offering a second option alongside Moderna's original vaccine, though its approval comes shortly after the Trump administration canceled funding for Moderna's pandemic flu vaccine development.

Analysis

The U.S. Food and Drug Administration (FDA) has approved Moderna's new lower-dose COVID-19 vaccine, mNexspike, marking an incremental development in its vaccine portfolio. This new vaccine utilizes a refined immune target, allowing for a dosage that is one-fifth of its existing Spikevax vaccine. The approval for mNexspike is specifically for adults aged 65 and older, and for individuals aged 12 to 64 with at least one health condition that puts them at increased risk from the coronavirus, a limitation mirroring the restrictions placed on Novavax's COVID-19 vaccine and noted as a departure from previous U.S. COVID-19 vaccine handling, reflecting skepticism from some officials. This targeted approval contrasts with Moderna's original Spikevax, which maintains broader authorization for individuals aged 6 months and older. According to Moderna, an 11,400-person study demonstrated mNexspike's safety and found it to be at least as effective — and more so by some measures — than the original Spikevax. While this approval provides a second COVID-19 vaccine option from Moderna, expected to be offered this fall, it follows shortly after the Trump administration canceled funding for Moderna's development of a pandemic flu vaccine. The per-ticker sentiment for MRNA is positive at 0.7, reflecting this product approval, though the general market impact score is moderate at 0.5, possibly tempered by the restricted use and the recent flu vaccine funding news.

Key Decisions for Investors

• Investors in Moderna should acknowledge the mNexspike approval as a positive development that could secure a niche in the specified high-risk demographics, but must also consider the limited scope compared to Spikevax and the recent setback in pandemic flu vaccine funding.
• The similar restrictions on mNexspike as on Novavax's vaccine suggest a consistent regulatory approach for newer COVID-19 vaccines, which may neutralize a competitive disadvantage for Novavax within this specific product category.
• Market participants should monitor the uptake of mNexspike, the overall trajectory of the COVID-19 vaccine market, and how governmental funding decisions might influence Moderna's broader pipeline and long-term growth.